Subscribe To
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
Company reports fourth quarter and full year 2022 XHANCE net revenue of $20.9 million and $76.3 million Company submitted sNDA for XHANCE label expansion in February 2023 Physicians diagnose chronic sinusitis 10 times more frequently than XHANCE’s current nasal polyps indication and there is no FDA-approved medication for these patients Conference call and webcast to […] The post Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights appeared first...
Read More
Posted: Mar 7 2023, 12:00
Author Name: forextv
Views: 102634